Sanjay Mohan

2.1k total citations
63 papers, 685 citations indexed

About

Sanjay Mohan is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Sanjay Mohan has authored 63 papers receiving a total of 685 indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Hematology, 33 papers in Genetics and 14 papers in Molecular Biology. Recurrent topics in Sanjay Mohan's work include Acute Myeloid Leukemia Research (37 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (25 papers) and Chronic Myeloid Leukemia Treatments (19 papers). Sanjay Mohan is often cited by papers focused on Acute Myeloid Leukemia Research (37 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (25 papers) and Chronic Myeloid Leukemia Treatments (19 papers). Sanjay Mohan collaborates with scholars based in United States, Italy and France. Sanjay Mohan's co-authors include Jaroslaw P. Maciejewski, Stephen A. Strickland, Quanhu Sheng, Michael R. Savona, Bart L. Scott, P. Brent Ferrell, Hugo F. Fernández, Dennis Dong Hwan Kim, Yan Guo and Scott D. Rowley and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Sanjay Mohan

61 papers receiving 681 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sanjay Mohan United States	13	406	333	199	89	84	63	685
Abid Mohiuddin United States	9	784 1.9×	565 1.7×	119 0.6×	412 4.6×	14 0.2×	15	857
Maria Cristina Rapanotti Italy	14	313 0.8×	171 0.5×	88 0.4×	163 1.8×	44 0.5×	28	598
Lisa Eidenschink Brodersen United States	12	470 1.2×	195 0.6×	146 0.7×	106 1.2×	59 0.7×	43	597
Elliot Stieglitz United States	13	292 0.7×	245 0.7×	135 0.7×	92 1.0×	45 0.5×	58	537
Montserrat Torrebadell Spain	10	354 0.9×	224 0.7×	189 0.9×	144 1.6×	57 0.7×	21	571
Giuseppina Tota Italy	16	269 0.7×	261 0.8×	153 0.8×	77 0.9×	154 1.8×	41	571
Sebastian Vosberg Germany	10	288 0.7×	227 0.7×	75 0.4×	157 1.8×	96 1.1×	20	570
Claudia Tschulik Germany	5	712 1.8×	391 1.2×	237 1.2×	132 1.5×	90 1.1×	9	828
Ryan J. Mattison United States	12	273 0.7×	238 0.7×	159 0.8×	111 1.2×	21 0.3×	58	518
Nicole Smadja France	9	484 1.2×	347 1.0×	153 0.8×	154 1.7×	20 0.2×	16	541

Countries citing papers authored by Sanjay Mohan

Since Specialization

Citations

This map shows the geographic impact of Sanjay Mohan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sanjay Mohan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sanjay Mohan more than expected).

Fields of papers citing papers by Sanjay Mohan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sanjay Mohan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sanjay Mohan. The network helps show where Sanjay Mohan may publish in the future.

Co-authorship network of co-authors of Sanjay Mohan

This figure shows the co-authorship network connecting the top 25 collaborators of Sanjay Mohan. A scholar is included among the top collaborators of Sanjay Mohan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sanjay Mohan. Sanjay Mohan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ali, Haris, Ashwin Kishtagari, Sanjay Mohan, et al.. (2024). Selinexor-Driven Regulation of Proinflammatory Cytokines May Lead to Stabilization of Hematologic Parameters and Bone Marrow Function in Patients with Myelofibrosis: Case Study from the Phase 1 Sentry Trial. Blood. 144(Supplement 1). 6676–6676. 1 indexed citations

Bose, Prithviraj, Hsin‐An Hou, Wojciech Homenda, et al.. (2024). Disease-Modifying Activity of Navtemadlin Correlates with Clinical Responses in a Randomized, Multicenter, Global Phase 3 Study (BOREAS) in JAK-Inhibitor Relapsed/Refractory Myelofibrosis. Blood. 144(Supplement 1). 483–483. 3 indexed citations

Popov, Viola Maria, Sanjay Mohan, Zübeyde Nur Özkurt, et al.. (2024). Results from the Randomized, Multicenter, Global Phase 3 BOREAS Study: Navtemadlin Versus Best Available Therapy in JAK Inhibitor Relapsed/Refractory Myelofibrosis. Blood. 144(Supplement 1). 1000–1000. 4 indexed citations

Tantravahi, Srinivas K., Ashwin Kishtagari, Sanjay Mohan, et al.. (2024). MPN-527 Selinexor and Ruxolitinib Impact on Symptom Burden in Patients With Myelofibrosis Is Potentially Driven by Inhibition of NF-κB and Activation of P53 Pathways. Clinical Lymphoma Myeloma & Leukemia. 24. S437–S438. 1 indexed citations

Raina, Ankush, et al.. (2024). Tribocorrosion of 3D printed dental implants: An overview. Journal of Taibah University Medical Sciences. 19(3). 644–663. 4 indexed citations

Ball, Somedeb, Michael Byrne, Melissa A. Fischer, et al.. (2024). Application of a Phenotype-Based Predictive Analytic in a Phase Ib Study of Selinexor and Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia. Blood. 144(Supplement 1). 6012–6012. 1 indexed citations

Zeidan, Amer M., Rachel J. Cook, Rodolfo Bordoni, et al.. (2022). A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies. Clinical Lymphoma Myeloma & Leukemia. 22(7). 523–534. 10 indexed citations

Verstovšek, Srđan, Haifa Kathrin Al‐Ali, John Mascarenhas, et al.. (2022). BOREAS: A Global, Phase III Study of the MDM2 Inhibitor Navtemadlin (KRT-232) in Relapsed/Refractory Myelofibrosis. Future Oncology. 18(37). 4059–4069. 21 indexed citations

Maziarz, Richard T., Mark J. Levis, Mrinal M. Patnaik, et al.. (2020). Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia. Bone Marrow Transplantation. 56(5). 1180–1189. 100 indexed citations

10.

Byrne, Michael, Salyka Sengsayadeth, Katie S. Gatwood, et al.. (2020). The use of venetoclax‐based salvage therapy for post‐hematopoietic cell transplantation relapse of acute myeloid leukemia. American Journal of Hematology. 95(9). 1006–1014. 44 indexed citations

11.

Bhatnagar, Bhavana, Sanjay Mohan, William Senapedis, et al.. (2019). Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Higher-Risk Myelodysplastic Syndrome. Blood. 134(Supplement_1). 2997–2997. 4 indexed citations

12.

Moyo, Tamara K., Justin M. Watts, Barry Skikne, et al.. (2019). Preliminary Results from a Phase II Study of the Combination of Pevonedistat and Azacitidine in the Treatment of MDS and MDS/MPN after Failure of DNA Methyltransferase Inhibition. Blood. 134(Supplement_1). 4236–4236. 10 indexed citations

13.

Strickland, Stephen A., Aaron C. Shaver, Michael Byrne, et al.. (2018). Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia. Leukemia Research. 65. 67–73. 10 indexed citations

14.

Ferrell, P. Brent, Kirsten E. Diggins, Hannah G. Polikowsky, et al.. (2016). High-Dimensional Analysis of Acute Myeloid Leukemia Reveals Phenotypic Changes in Persistent Cells during Induction Therapy. PLoS ONE. 11(4). e0153207–e0153207. 33 indexed citations

15.

Zhao, Yue, Qi Liu, Pankaj Acharya, et al.. (2016). High-Resolution Mapping of RNA Polymerases Identifies Mechanisms of Sensitivity and Resistance to BET Inhibitors in t(8;21) AML. Cell Reports. 16(7). 2003–2016. 59 indexed citations

16.

Maziarz, Richard T., Mrinal M. Patnaik, Bart L. Scott, et al.. (2016). Radius: A Phase 2, Randomized Trial of Standard of Care (SOC) with or without Midostaurin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT) in Patients (pts) with FLT3-Itd-Mutated Acute Myeloid Leukemia (AML). Blood. 128(22). 2248–2248. 17 indexed citations

17.

Roboz, Gail J., Pau Montesinos, Dominik Selleslag, et al.. (2016). Design of the Randomized, Phase III, QUAZAR AML Maintenance Trial of CC-486 (Oral Azacitidine) Maintenance Therapy in Acute Myeloid Leukemia. Future Oncology. 12(3). 293–302. 29 indexed citations

18.

Mohan, Sanjay & Anjali S. Advani. (2011). Treatment of Acute Lymphoblastic Leukemia in Adolescents and Young Adults. Journal of Adolescent and Young Adult Oncology. 1(1). 19–24. 6 indexed citations

19.

Jankowska, Ania, Hadrian Szpurka, Maria Grazia Calabró, et al.. (2011). Loss of expression of neutrophil proteinase-3: a factor contributing to thrombotic risk in paroxysmal nocturnal hemoglobinuria. Haematologica. 96(7). 954–962. 9 indexed citations

20.

Mohan, Sanjay & Jaroslaw P. Maciejewski. (2008). Diagnosis and therapy of neutropenia in large granular lymphocyte leukemia. Current Opinion in Hematology. 16(1). 27–34. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact